Details for Patent: 10,500,216
✉ Email this page to a colleague
Which drugs does patent 10,500,216 protect, and when does it expire?
Patent 10,500,216 protects KORLYM and is included in one NDA.
Summary for Patent: 10,500,216
| Title: | Optimizing mifepristone absorption |
| Abstract: | The present invention provides a method for altering the pharmacokinetics of mifepristone upon oral administration. Mifepristone absorption into the blood is increased upon administration with meals. The method of the invention can benefit patients suffering from conditions including psychiatric illnesses and hormonal disorders. |
| Inventor(s): | Belanoff; Joe (Menlo Park, CA), Roe; Robert (Menlo Park, CA), Loewy; Caroline (Menlo Park, CA) |
| Assignee: | Corcept Therapeutics, Inc. (Menlo Park, CA) |
| Application Number: | 13/677,465 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,500,216 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 10,500,216
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therap | KORLYM | mifepristone | TABLET;ORAL | 202107-001 | Feb 17, 2012 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATING CUSHING'S SYNDROME | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
